Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Drugs Made In America Acquisition Corp. Units (DMAAU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: DMAAU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0.86% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 10.00 - 124.00 | Updated Date 05/1/2025 |
52 Weeks Range 10.00 - 124.00 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Drugs Made In America Acquisition Corp. Units
Company Overview
History and Background
Drugs Made In America Acquisition Corp. is a blank check company incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It was founded in 2020.
Core Business Areas
- Special Purpose Acquisition Company (SPAC): Drugs Made In America Acquisition Corp. is a SPAC, meaning its primary business is to identify and acquire a private company, bringing it public without a traditional IPO.
Leadership and Structure
The company is led by its management team, which typically consists of executives with experience in finance and deal-making. The organizational structure is simple, focused on identifying and completing an acquisition.
Top Products and Market Share
Key Offerings
- SPAC Structure: Drugs Made In America Acquisition Corp. offers investors the opportunity to invest in a potential future acquisition target. Market share is not applicable as it's a SPAC before acquisition.
Market Dynamics
Industry Overview
The SPAC market is dynamic, with periods of high activity followed by corrections. The performance of SPACs varies greatly depending on the quality of the acquired company.
Positioning
Drugs Made In America Acquisition Corp. is positioned as a vehicle for taking a private company public. Success depends on its ability to find a suitable target with growth potential.
Total Addressable Market (TAM)
The TAM is the aggregate valuation of all private companies that could potentially go public via a SPAC, estimated to be in the trillions of dollars. Drugs Made In America Acquisition Corp. targets a specific subset, depending on its investment mandate.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Access to public capital markets
- Potential for high returns if a good acquisition is made
Weaknesses
- Blank check nature creates uncertainty
- High fees and expenses
- Dependence on finding a suitable acquisition target
Opportunities
- Growing demand for alternative ways to go public
- Potential to acquire a high-growth company
- Favorable market conditions for SPAC mergers
Threats
- Increased regulatory scrutiny of SPACs
- Competition from other SPACs
- Market volatility impacting deal valuations
Competitors and Market Share
Key Competitors
- Other SPACs such as: CFVI
- DWAC
- GGPI
- DNA
- IPOF
Competitive Landscape
Drugs Made In America Acquisition Corp. competes with other SPACs for attractive acquisition targets. Its competitive advantage depends on its management team's expertise and deal-making ability.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to finding and closing an acquisition. Before acquisition, growth is not relevant.
Future Projections: Future growth depends entirely on the acquisition target and its subsequent performance.
Recent Initiatives: Recent initiatives focus on identifying and evaluating potential acquisition targets.
Summary
Drugs Made In America Acquisition Corp. is a SPAC seeking an acquisition target. Its strength lies in its management team, but its success hinges on finding a suitable company to merge with. Investors should carefully consider the risks associated with SPACs, including the potential for dilution and the uncertainty surrounding the acquisition target.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Financial news sources
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. SPAC investments are inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Drugs Made In America Acquisition Corp. Units
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2025-01-28 | CEO & Executive Chairman Ms. Lynn Stockwell | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://dmaacorp.com |
Full time employees - | Website https://dmaacorp.com | ||
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.